Cargando…
Topotecan in the treatment of relapsed small cell lung cancer
Small cell lung cancer (SCLC) represents about 15% to 20% of all lung cancers. Chemotherapy is the cornerstone of the treatment, cisplatin–etoposide combination being the most used combination as first-line therapy. Despite high initial chemosensitivity, most SCLC patients will experience relapse so...
Autor principal: | Quoix, Elisabeth |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994215/ https://www.ncbi.nlm.nih.gov/pubmed/21127755 |
Ejemplares similares
-
Topotecan: An evolving option in the treatment of relapsed small cell lung cancer
por: Garst, Jennifer
Publicado: (2007) -
Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer
por: Riemsma, Rob, et al.
Publicado: (2010) -
Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis
por: Imai, Hisao, et al.
Publicado: (2018) -
Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients
por: Horita, Nobuyuki, et al.
Publicado: (2015) -
Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after
amrubicin monotherapy failure
por: Fujita, Kohei, et al.
Publicado: (2021)